How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?

The therapeutic algorithm in stage >I lymphocyte predominant HL is extrapolated from data on classic HL. Thus, I would use the same algorithm as in HL when evaluating RT indication and dose.

Omitting radiotherapy is safe, if a favorable response has been documented on PET-CT and the patient has rece...